Search

Perfluoroalkyl substances (PFASs) is a growing class of contaminants in the Arctic environment, and include the established perfluorinated sulfonates (PFSAs; especially perfluorooctane sulfonate (PFOS)) and carboxylic acids (PFCAs). PFSAs and PFCAs of varying chain length have been reported to bioaccumulate in lipid rich tissues of the brain among other tissues such as liver, and can reach high concentrations in top predators including the polar bear. PFCA and PFSA bioaccummulation in the brain has the potential to pose neurotoxic effects and therefore we conducted a study to investigate if variations in neurochemical transmitter systems i.e. the cholinergic, glutaminergic, dopaminergic and GABAergic, could be related to brain-specific bioaccumulation of PFASs in East Greenland polar bears. Nine brain regions from nine polar bears were analyzed for enzyme activity (monoamine oxidase (MAO), acetylcholinesterase (AChE) and glutamine synthetase (GS)) and receptor density (dopamine-2 (D2), muscarinic cholinergic (mAChR) and gamma-butyric acid type A (GABA-A)) along with PFSA and PFCA concentrations. Average brain ∑PFSA concentration was 25 ng/g ww where PFOS accounted for 91%. Average ∑PFCA concentration was 88 ng/g ww where PFUnDA, PFDoDA and PFTrDA combined accounted for 79%. The highest concentrations of PFASs were measured in brain stem, cerebellum and hippocampus. Correlative analyses were performed both across and within brain regions. Significant positive correlations were found between PFASs and MAO activity in occipital lobe (e.g. ∑PFCA; r p¼0.83, p¼0.041, n¼6) and across brain regions (e.g. ∑PFCA; rp¼0.47, p ¼0.001, ∑PFSA; rp¼0.44, p40.001; n¼50). GABA-A receptor density was positively correlated with two PFASs across brain regions (PFOS; rp ¼0.33, p¼0.02 and PFDoDA; rp ¼0.34, p ¼0.014; n¼52). Significant negative correlations were found between mAChR density and PFASs in cerebellum (e.g. ∑PFCA; rp ¼� 0.95, p¼0.013, n¼5) and across brain regions (e.g. ∑PFCA; rp ¼� 0.40, p¼0.003, ∑PFSA; rp ¼� 0.37, p ¼0.007; n¼52). AChE activity and D2 density were negatively correlated with single PFCAs in several brain regions, whereas GS activity was positively correlated with PFASs primarily in occipital lobe. Results from the present study support the hypothesis that PFAS concentrations in polar bears from East Greenland have exceeded the threshold limits for neurochemical alterations. It is not known whether the observed alterations in neurochemical signaling are currently having negative effects on neurochemistry in East Greenland polar bears. However given the importance of these systems in cognitive processes and motor function, the present results indicate an urgent need for a better understanding of neurochemical effects of PFAS exposure to wildlife.

Although recent usage of organophosphate (OP) flame retardants has increased substantially, very few studies have reported on OPs in biota including wildlife, and essentially there is no information on OP body compartment composition and in ovo or in utero transfer for any given wildlife species. Concentrations and patterns of 16 OP triesters were presently screened for and/or determined in six body compartments from female herring gulls (Larus argentatus; n=8) and the separate egg yolk and albumen of their entire clutches of eggs (n=16) (collected in 2010 from a Lake Huron colony site, Laurentian Great Lakes of North America). Fat (32.3±9.8 ng/g wet weight; ww) contained the highest ΣOP concentration, followed by egg yolk (14.8±2.4 ng/g ww)≈egg albumen (14.8±5.9 ng/g ww)>muscle (10.9±5.1 ng/g ww)≫red blood cells (1.00±0.62 ng/g ww), whereas in liver, blood plasma, and brain all OPs were not detectable. Nine OPs accumulated in herring gulls, but the concentrations and proportions of OPs were dependent on the body and egg compartment. For example, tris(2-butoxyethyl) phosphate (TBOEP) accounted for 66% of the ΣOP concentration in albumen, but only for 13% in yolk. Tri-n-butyl phosphate (TNBP) accounted for 25% of the ΣOP concentration in yolk, but was not detected in albumen. Estimates showed that overall OP burdens in the body (3.5 μg) were greater than in the whole egg (1.2 μg), although depuration via in ovo transfer was substantial.

Several perfluoroalkyl carboxylates (PFCAs) and perfluoroalkyl sulfonates (PFSAs) of varying chain length are bioaccumulative in biota. However, wildlife reports have focused on liver and with very little examination of other tissues, and thus there is a limited understanding of their distribution and potential effects in the mammalian body. In the present study, the comparative accumulation of C(6) to C(15) PFCAs, C(4), C(6), C(8) and C(10) PFSAs, and select precursors were examined in the liver, blood, muscle, adipose, and brain of 20 polar bears (Ursus maritimus) from Scoresby Sound, Central East Greenland. Overall, PFSA and PFCA concentrations were highest in liver followed by bloodbrainmuscle ≈ adipose. Liver and blood samples contained proportionally more of the shorter/medium chain length (C(6) to C(11)) PFCAs, whereas adipose and brain samples were dominated by longer chain (C(13) to C(15)) PFCAs. PFCAs with lower lipophilicities accumulated more in the liver, whereas the brain accumulated PFCAs with higher lipophilicities. The concentration ratios (±SE) between perfluorooctane sulfonate and its precursor perfluorooctane sulfonamide varied among tissues from 9 (±1):1 (muscle) to 36 (±7):1 (liver). PFCA and PFSA patterns in polar bears indicate that the pharmacokinetics of these compounds are to some extent tissue-specific, and are the result of several factors that may include differing protein interactions throughout the body.

The present study investigated the comparative accumulation of perfluoroalkyl acids (PFAAs) in eight brain regions of polar bears (Ursus maritimus, n = 19) collected in 2006 from Scoresby Sound, East Greenland. The PFAAs studied were perfluoroalkyl carboxylates (PFCAs, C(6) -C(15) chain lengths) and sulfonates (C(4) , C(6) , C(8) , and C(10) chain lengths) as well as selected precursors including perfluorooctane sulfonamide. On a wet-weight basis, blood-brain barrier transport of PFAAs occurred for all brain regions, although inner regions of the brain closer to incoming blood flow (pons/medulla, thalamus, and hypothalamus) contained consistently higher PFAA concentrations compared to outer brain regions (cerebellum, striatum, and frontal, occipital, and temporal cortices). For pons/medulla, thalamus, and hypothalamus, the most concentrated PFAAs were perfluorooctane sulfonate (PFOS), ranging from 47 to 58 ng/g wet weight, and perfluorotridecanoic acid, ranging from 43 to 49 ng/g wet weight. However, PFOS and the longer-chain PFCAs (C(10) -C(15) ) were significantly (p 0.002) positively correlated with lipid content for all brain regions. Lipid-normalized PFOS and PFCA (C(10) -C(15) ) concentrations were not significantly (p 0.05) different among brain regions. The burden of the sum of PFCAs, perfluoroalkyl sulfonates, and perfluorooctane sulfonamide in the brain (average mass, 392 g) was estimated to be 46 µg. The present study demonstrates that both PFCAs and perfluoroalkyl sulfonates cross the blood-brain barrier in polar bears and that wet-weight concentrations are brain region-specific.